DK0641203T3 - Farmaceutiske præparater af et imidazolyl-alkensyresalt og anvendelse heraf som angiotensin-II-antagonister - Google Patents

Farmaceutiske præparater af et imidazolyl-alkensyresalt og anvendelse heraf som angiotensin-II-antagonister

Info

Publication number
DK0641203T3
DK0641203T3 DK92918356T DK92918356T DK0641203T3 DK 0641203 T3 DK0641203 T3 DK 0641203T3 DK 92918356 T DK92918356 T DK 92918356T DK 92918356 T DK92918356 T DK 92918356T DK 0641203 T3 DK0641203 T3 DK 0641203T3
Authority
DK
Denmark
Prior art keywords
angiotensin
imidazolyl
antagonists
acid salt
pharmaceutical preparations
Prior art date
Application number
DK92918356T
Other languages
Danish (da)
English (en)
Inventor
Joseph Weinstock
Richard Mcculloch Keenan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK0641203T3 publication Critical patent/DK0641203T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK92918356T 1991-08-14 1992-08-12 Farmaceutiske præparater af et imidazolyl-alkensyresalt og anvendelse heraf som angiotensin-II-antagonister DK0641203T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/746,262 US5185351A (en) 1989-06-14 1991-08-14 Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
PCT/US1992/006734 WO1993003722A1 (en) 1991-08-14 1992-08-12 Imidazolyl-alkenoic acids

Publications (1)

Publication Number Publication Date
DK0641203T3 true DK0641203T3 (da) 2003-02-17

Family

ID=25000103

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92918356T DK0641203T3 (da) 1991-08-14 1992-08-12 Farmaceutiske præparater af et imidazolyl-alkensyresalt og anvendelse heraf som angiotensin-II-antagonister

Country Status (32)

Country Link
US (1) US5185351A (Direct)
EP (1) EP0641203B1 (Direct)
JP (1) JPH07500579A (Direct)
CN (1) CN1036396C (Direct)
AP (3) AP525A (Direct)
AT (1) ATE226073T1 (Direct)
AU (1) AU667824B2 (Direct)
BG (1) BG61593B1 (Direct)
BR (1) BR9206443A (Direct)
CA (1) CA2115170C (Direct)
CZ (1) CZ281635B6 (Direct)
DE (1) DE69232817T2 (Direct)
DK (1) DK0641203T3 (Direct)
ES (1) ES2185617T3 (Direct)
FI (1) FI114796B (Direct)
HU (1) HU225048B1 (Direct)
IL (1) IL102813A (Direct)
MA (1) MA22626A1 (Direct)
MX (1) MX9204737A (Direct)
MY (1) MY110205A (Direct)
NO (1) NO305172B1 (Direct)
NZ (1) NZ243966A (Direct)
OA (1) OA09884A (Direct)
PL (1) PL177234B1 (Direct)
PT (1) PT100779B (Direct)
RO (1) RO113643B1 (Direct)
RU (1) RU2124513C1 (Direct)
SK (1) SK281252B6 (Direct)
TW (1) TW234690B (Direct)
UA (1) UA40587C2 (Direct)
WO (1) WO1993003722A1 (Direct)
ZA (1) ZA926133B (Direct)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5418250A (en) * 1989-06-14 1995-05-23 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US6034114A (en) * 1990-12-14 2000-03-07 Smithkline Beecham Plc Medicament
US6028091A (en) * 1990-12-14 2000-02-22 Smithkline Beecham Plc Medicament
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
US5447949A (en) * 1991-05-15 1995-09-05 Smithkline Beecham Corporation N-(heteroaryl) imidazolyl-alkenoic acids having angiotension II receptor antagonist activity
US20030166700A1 (en) * 1991-12-12 2003-09-04 Smithkline Beecham P.L.C. Medicament
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
DE4206043A1 (de) * 1992-02-27 1993-09-02 Bayer Ag Sulfonylbenzyl-substituierte imidazole
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5824696A (en) * 1993-09-01 1998-10-20 Smithkline Beecham Corporation Medicaments
US5395847A (en) * 1993-12-02 1995-03-07 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
NZ285588A (en) * 1994-05-20 1997-12-19 Smithkline Beecham Corp [2-butyl-3-(4-carboxybenzyl)-1h-imidazolium-4-yl]-hydroxymethyl sulphonate
BR9508178A (pt) * 1994-06-29 1997-11-18 Smithkline Beecham Corp Antagonistas de receptor de vitronectina
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US6613789B2 (en) 1994-07-28 2003-09-02 G. D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US6420412B2 (en) 1996-03-29 2002-07-16 Smithkline Beecham Corporation Eprosartan dihydate and a process for its production and formulation
NZ332008A (en) * 1996-03-29 1999-05-28 Smithkline Beecham Corp Eprosartan dihydrate and a process for its production and formulation
AR011126A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano y compuestos intermediarios.
AR011125A1 (es) * 1997-02-14 2000-08-02 Smithkline Beecham Corp Procedimiento para preparar eprosartano
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
ZA984421B (en) * 1997-05-27 1998-11-27 Smithkline Beecham Corp Method of treating isolated systolic hypertension
US6262102B1 (en) 1997-06-27 2001-07-17 Smithkline Beecham Corporation Eprosartan monohydrate
WO1999007365A1 (en) * 1997-08-06 1999-02-18 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
US6630498B2 (en) 1997-08-06 2003-10-07 Smithkline Beecham Corporation Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
HUP0004407A3 (en) * 1997-11-17 2002-03-28 Smithkline Beecham Corp Immediate and modified release oral dosage formulations containing eprosartan and processes for their manufacture
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
CN1198591C (zh) * 1998-07-20 2005-04-27 史密丝克莱恩比彻姆公司 在口服固体剂型中包含依普沙坦的生物利用度提高的制剂
ATE288900T1 (de) 1998-07-24 2005-02-15 Bayer Cropscience Ag Substituierte benzoylcyclohexandione
DE19920791A1 (de) * 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19946853A1 (de) 1999-09-30 2001-04-05 Bayer Ag Substituierte Arylketone
DE10004084A1 (de) * 2000-01-31 2001-08-02 Bayer Ag Substituierte Imid-Derivate
DE10221121A1 (de) * 2002-05-13 2003-12-04 Bayer Cropscience Ag N'-Cyano-N-methyl-imidamid-Derivate
BR0313593A (pt) 2002-08-19 2005-07-12 Pfizer Prod Inc Terapia de combinação para doenças hiperproliferativas
OA13174A (en) * 2003-05-30 2006-12-13 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors.
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
PL1673107T3 (pl) * 2003-10-10 2008-06-30 Abbott Laboratories Gmbh Kompozycja farmaceutyczna zawierająca selektywnego agonistę receptora imidazoliny I1 i bloker receptora angiotensyny II
US20060099230A1 (en) * 2004-11-10 2006-05-11 Chin-Chih Chiang Novel formulations of eprosartan with enhanced bioavailability
EP1819681B1 (en) * 2004-11-23 2009-08-12 Warner-Lambert Company LLC 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
EP1752450A1 (en) 2005-08-01 2007-02-14 Merck Sante Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
WO2007054896A1 (en) * 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US20090270474A1 (en) * 2005-12-06 2009-10-29 Keiichi Shibagaki Therapeutic Agent for Keratoconjunctival Disorder
WO2008020314A2 (en) * 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
WO2008010087A2 (en) * 2006-07-14 2008-01-24 Ranbaxy Laboratories Limited Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
US20080014263A1 (en) * 2006-07-17 2008-01-17 Glenmark Pharmaceuticals Limited Amorphous eprosartan mesylate and process for the preparation thereof
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20100137613A1 (en) * 2006-12-27 2010-06-03 Hetero Drugs Limited Process for eprosartan
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009013760A2 (en) * 2007-07-25 2009-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
EP2295430A3 (en) * 2007-07-25 2011-08-03 Hetero Drugs Limited Crystalline solid of eprosartan acetate
JP2011500783A (ja) * 2007-10-22 2011-01-06 オーキッド リサーチ ラボラトリーズ リミテッド ヒストンデアセチラーゼ阻害剤
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101215284B (zh) * 2007-12-31 2010-10-13 浙江华海药业股份有限公司 一种改进的依普罗沙坦的制备方法
US20110054186A1 (en) * 2008-03-31 2011-03-03 Hetero Research Foundation Process for eprosartan intermediate
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CN101333216A (zh) * 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
WO2011004384A2 (en) 2009-06-05 2011-01-13 Glochem Industries Limited Process for the preparation of eprosartan
WO2011051975A1 (en) 2009-10-30 2011-05-05 Matrix Laboratories Ltd An improved process for the preparation of pure eprosartanand its pharmaceutical acceptable salts
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
RU2525156C2 (ru) * 2010-07-15 2014-08-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ лечения и профилактики артериальной гипертензии и фармацевтическая композиция для лечения артериальной гипертензии
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2846387C (en) 2011-08-26 2016-02-09 Wockhardt Limited Methods for treating cardiovascular disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
EP3025711B1 (en) 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medicine for preventing or treating hypertension
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP6934859B2 (ja) 2016-03-24 2021-09-15 第一三共株式会社 腎疾患の治療のための医薬
CA3103599A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
AU2020209215B2 (en) 2019-01-18 2023-02-02 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS58157768A (ja) * 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
US4668794A (en) * 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
DE69033469T2 (de) * 1989-06-14 2000-09-07 Smithkline Beecham Corp., Philadelphia Imidazoalkensäure
CA2027937A1 (en) * 1989-10-25 1991-04-26 Richard M. Keenan Substituted 5-¬ (tetrazolyl)alkenyl|imidazoles
GB9027197D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027209D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027210D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
ES2130170T3 (es) * 1990-12-14 1999-07-01 Smithkline Beecham Corp Composiciones bloqueantes del receptor de la angiotensina ii.
GB9027198D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027211D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027201D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027212D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027199D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
GB9027200D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments

Also Published As

Publication number Publication date
AP526A (en) 1996-09-06
JPH07500579A (ja) 1995-01-19
WO1993003722A1 (en) 1993-03-04
DE69232817D1 (de) 2002-11-21
AP9500742A0 (en) 1995-07-31
PT100779B (pt) 1999-07-30
EP0641203A4 (en) 1994-06-09
MX9204737A (es) 1994-02-28
NO940476D0 (no) 1994-02-11
CA2115170C (en) 2004-05-25
BR9206443A (pt) 1994-09-27
RU2124513C1 (ru) 1999-01-10
FI940642A0 (fi) 1994-02-11
HK1012246A1 (en) 1999-07-30
NZ243966A (en) 1996-08-27
PT100779A (pt) 1993-09-30
CZ31194A3 (en) 1994-12-15
NO305172B1 (no) 1999-04-12
AP9200416A0 (en) 1992-10-31
MA22626A1 (fr) 1993-04-01
AP525A (en) 1996-09-06
FI940642L (fi) 1994-02-11
HU225048B1 (en) 2006-05-29
SK13594A3 (en) 1994-08-10
DE69232817T2 (de) 2003-06-18
ATE226073T1 (de) 2002-11-15
EP0641203A1 (en) 1995-03-08
US5185351A (en) 1993-02-09
IL102813A0 (en) 1993-01-31
CN1036396C (zh) 1997-11-12
ZA926133B (en) 1993-03-31
EP0641203B1 (en) 2002-10-16
CN1070645A (zh) 1993-04-07
NO940476L (no) 1994-04-11
BG61593B1 (bg) 1998-01-30
IL102813A (en) 1999-07-14
RO113643B1 (ro) 1998-09-30
BG98454A (bg) 1995-02-28
PL177234B1 (pl) 1999-10-29
SK281252B6 (sk) 2001-01-18
OA09884A (en) 1994-09-15
TW234690B (Direct) 1994-11-21
HUT70157A (en) 1995-09-28
ES2185617T3 (es) 2003-05-01
FI114796B (fi) 2004-12-31
CA2115170A1 (en) 1993-03-04
AU2475692A (en) 1993-03-16
AP527A (en) 1996-09-06
AU667824B2 (en) 1996-04-18
UA40587C2 (uk) 2001-08-15
AP9500741A0 (en) 1995-07-31
MY110205A (en) 1998-02-28
HU9400413D0 (en) 1994-05-30
CZ281635B6 (cs) 1996-11-13

Similar Documents

Publication Publication Date Title
DK0641203T3 (da) Farmaceutiske præparater af et imidazolyl-alkensyresalt og anvendelse heraf som angiotensin-II-antagonister
FI932517A0 (fi) Antagonister av angiotensin II
BR1100329A (pt) Composto e formulação farmacêutica
DK272389A (da) Anvendelse af gamma-hydroxysmoersyresalte til fremstilling af farmaceutiske praeparater til behandling af alkoholisme og praeparater opnaaet herved
NO305317B1 (no) Sulfonamid-endotelin-antagonister anvendelser derav og farmas°ytisk preparat
NO20021401D0 (no) Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
DK414189A (da) Aminosyreforbindelse og dens anvendelse
NO922506D0 (no) Farmasoeytiske preparat
NO933647L (no) Karboksylsyrederivater, legemidler inneholdende disse og fremgangsmåte for deres fremstilling
KR950704251A (ko) 프롤릴 엔도펩티다아제 억제 활성을 갖는 화합물 및 그 약학적 용도(compound with prolyl endopeptdase inhibitor activity and pharmaceutical use thereof)
DK611489D0 (da) Anxiolytisk aktive piperazinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser
FI950089A7 (fi) Dioksosyklobuteenijohdannaiset angiotensiini-II-antagonisteina
FI922905A7 (fi) Imidatsoliyhdisteiden valmistus ja käyttö
DK162491D0 (da) Heterocycliske forbindelser, deres fremstilling og farmaceutiske praeparater indeholdende forbindelserne
ITMI921413A0 (it) Preparazioni farmaceutiche stabili di nicorandil
DK204291D0 (da) Heterocykliske forbindelser deres fremstilling og anvendelse
PT1228039E (pt) N-guanidinoalquilamidas sua preparacao sua utilizacao e preparacoes farmaceuticas contendo as mesmas
FI20001777A7 (fi) Substituoidun triatsolin sulfaattisuola ja sen farmaseuttisia koostumuksia
DK144491D0 (da) Boejle til inseminering af grisesoeer
DK226488A (da) Anvendelse af ace-inhibitorer til fremstilling af farmaceutiske praeparater
DK522788A (da) Amidinoderivater og farmaceutiske praeparater med indhold af saadanne forbindelser
FI931701A7 (fi) Rasvan muodostumista ehkäisevän tekijän johdannaiset, niiden valmistus ja käyttö
NO930796D0 (no) Glykopeptidderivater, fremgangsmaate for deres fremstilling og farmasoeytiske midler inneholdende disse
MX9207429A (es) Nuevo uso de derivados de aminoacido.
DK522888D0 (da) Heterocykliske derivater og farmaceutiske praeparater med indhold af saadanne